SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-24-037717
Filing Date
2024-04-30
Accepted
2024-04-30 14:38:47
Documents
92
Period of Report
2023-12-31

Document Format Files

Seq Description Document Type Size
1 ANNUAL REPORT ea0204561-20f_xtlbiopharma.htm   iXBRL 20-F 1705640
2 CERTIFICATION ea020456101ex12-1_xtlbio.htm EX-12.1 11318
3 CERTIFICATION ea020456101ex12-2_xtlbio.htm EX-12.2 11118
4 CERTIFICATION ea020456101ex13-1_xtlbio.htm EX-13.1 5478
5 CLAWBACK POLICY ea020456101ex99-7_xtlbio.htm EX-99.7 70977
6 GRAPHIC image_001.jpg GRAPHIC 21972
  Complete submission text file 0001213900-24-037717.txt   6606124

Data Files

Seq Description Document Type Size
7 XBRL SCHEMA FILE xtlb-20231231.xsd EX-101.SCH 96648
8 XBRL CALCULATION FILE xtlb-20231231_cal.xml EX-101.CAL 32772
9 XBRL DEFINITION FILE xtlb-20231231_def.xml EX-101.DEF 245591
10 XBRL LABEL FILE xtlb-20231231_lab.xml EX-101.LAB 522793
11 XBRL PRESENTATION FILE xtlb-20231231_pre.xml EX-101.PRE 257543
96 EXTRACTED XBRL INSTANCE DOCUMENT ea0204561-20f_xtlbiopharma_htm.xml XML 986464
Mailing Address 5 HACHAROSHET ST. RAANANA L3 4365603
Business Address XTL BIOPHARMACEUTICALS LTD C/O ALSTON & BIRD LLP, 90 PARK AVENUE NEW YORK NY 10016 972 9 955 7080
XTL BIOPHARMACEUTICALS LTD (Filer) CIK: 0001023549 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3
Type: 20-F | Act: 34 | File No.: 001-36000 | Film No.: 24896396
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)